Sepsis Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Sepsis Therapeutics Market Analysis
The sepsis therapeutics market is projected to register a CAGR of 7.6% over the forecast period.
The COVID-19 pandemic affected the treatment and diagnostics procedures other than COVID-19 which had a significant impact on the studied market. The COVID-19 virus was also added to the list of pathogens that cause sepsis. For instance, an article titled "Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19" published in Frontiers in Immunology Journal in February 2021 stated that both SARS-CoV-2 infection and sepsis shared many pathophysiological and clinical features. Managing COVID, in the beginning, followed the sepsis management guidelines. Most patients who were critically ill with COVID-19 developed sepsis, a significant threat to their survival. Overall, the COVID-19 pandemic is anticipated to have had a positive impact on the market studied.
Sepsis can result from an infection anywhere in the body, such as pneumonia, influenza, or urinary tract infections. The COVID-19 pandemic increased surveillance of the infectious virus among people. Various countries, along with testing for COVID-19 in the test sample given by the symptomatic patient, were also testing for influenza virus, which is a major reason of sepsis. The increased diagnosis of bacterial and viral infection is expected to affect the market in a positive way, as people became aware about the sepsis therapeutics and company activities also increased. Hence COVID-19 viral infection worldwide is bolstering the need to expedite the research and development activities to develop sepsis therapeutics and ultimately augmenting the market growth.
In addition, the increasing incidence of sepsis, high prevalence of sepsis in infants, and rise in the number of pipeline products, and a surge in research and development expenditures are actively affecting the growth of the studied market.
The engagement of pharmaceutical companies and healthcare institutions in research and development activities to develop a noval treatment for sepsis is projected to augment the market growth. For instance, in October 2021, Matinas BioPharma initiated dosing in phase 1 study of one of the first oral aminoglycoside antibiotic drugs MAT2501. The surge in clinical trial activities is likely to augment the market growth.
Additionally, the funding by the government to expedite research activities for sepsis management is likely to create awareness about the disease among the population and ultimately boost market growth. For instance, according to the Canadian Institutes of Health Research July 2020 report, the Government of Canada invested USD 5.7 million to support Sepsis Canada, a new national research network that is expected to improve the treatment and recovery of sepsis patients. 190 clinicians, scientists, and patient representatives from all over Canada came together as part of Sepsis Canada. Such initiatives are anticipated to augment the market growth.
Therefore, owing to the abovementioned factors, the studied market is anticipated to witness growth over the analysis period. however, a lack of an initial diagnostic test for identifying sepsis conditions and a lack of awareness are likely to impede the market growth.
Sepsis Therapeutics Market Trends
This section covers the major market trends shaping the Sepsis Therapeutics Market according to our research experts:
Cephalosporins Are Expected To Witness Growth Over The Forecast Period
Cephalosporins are divided into the first, second, third, and fourth generations. First-generation cephalosporins have more significant activity against gram-positive bacteria. The succeeding generations have increased activity against gram-negative bacteria.
The dominant share of the segment is attributed to the extensive usage of the drug class, individually or in combination with the other drugs. For instance, the research article titled "Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective" published in Frontiers in Medicine Journal in May 2021, stated that ceftobiprole medocaril is currently approved in Europe as an extended-spectrum cephalosporin for adult community-acquired and nosocomial, non-ventilator-associated pneumonia and skin and soft tissue infection (SSTIs), including diabetic foot infections. The segment is expected to grow due to the advantages of cephalosporins during the forecast period.
Additionally, according to an article titled "Sepsis Management in Southeast Asia: A Review and Clinical Experience" published in the Journal of Clinical Medicine in June 2022, a recent study conducted in Southeast Asian region reported that 48% of adults and 56% of children were affected with sepsis and severe sepsis. According to the study, sepsis affected 65% of ICU patients in India, and there was a 25% fatality rate, making it the Southeast Asian nation with the second-highest sepsis mortality rate. The high burden of sepsis worldwide and its fatal effects is projected to augment the use of cephalosporins to treat it which is ultimately projected to boost the segment growth.
The increasing product approvals, launches, and acquisitions by the key market players are expected to boost the segment's growth during the forecast period. For instance, in October 2021, Sandoz, a Novartis division, acquired GSK's cephalosporin antibiotics business. It now has the rights to three well-known brands (Zinnat, Zinacef, and Fortum) in more than 100 markets. Such company developments are projected to boost the segment growth.
North America is Expected to Dominate the Sepsis Therapeutics Market Over The Forecast Period
North America is expected to dominate the market owing to factors such as the high prevalence of sepsis, chronic illness, the strong presence of industry players in the region, better healthcare infrastructure, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the region.
The Providence Health Care September 2022 article stated that sepsis is most prominent in infants and children and affects 40,000 to 50,000 individuals each year in Canada and it is the 12th leading cause of death in Canada. The article also stated that according to the Canadian Sepsis Foundation USD 325 million is spent annually on treating sepsis in Canada. The large patient pool and high disease spending propel the region's market growth.
Additionally, according to the Centers for Disease Control and Prevention (CDC), 2022 update, at least 1.7 million adults in the United States suffer from sepsis. It also stated that 1 out of 3 people's deaths in a hospital is because of sepsis during that hospitalization. Sepsis cases in the United States have increased steadily and leading to the growth of the studied market in the region.
Therefore, owing to the above-mentioned factors, the growth of the studied market is anticipated in the North America Region.
Sepsis Therapeutics Industry Overview
The sepsis therapeutics market is slightly consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. Some of the companies currently dominating the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., GSK Plc, Viatris Inc (Mylan Inc.), AbbVie Inc. (Allergan Pharmaceuticals International Limited), Endacea Inc., Adrenomed AG, and RegeneRx.
Sepsis Therapeutics Market Leaders
-
Pfizer Inc.
-
F. Hoffmann-La Roche Ltd
-
Viatris Inc (Mylan Inc.)
-
GSK Plc
-
AbbVie Inc. (Allergan Pharmaceuticals International Limited)
*Disclaimer: Major Players sorted in no particular order
Sepsis Therapeutics Market News
- In May 2022, Phathom Pharmaceuticals, Inc. received the United States Food and Drug Administration (FDA) approval for VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori (H. pylori) infection in adults. The two New Drug Applications for these products were previously granted as qualified infectious disease products (QIDP).
- In May 2022, Sepsis Alliance launched Sepsis Innovation Collaborative (SIC). The goals of SIC include enhancing early diagnosis, developing better antimicrobial therapies and host modifying agents, and many more. It is one of the first public-private collaborative communities dedicated to innovation in combatting sepsis. The members include Beckman Coulter, Merck, BioAegis Therapeutics, Roche, and other companies.
Sepsis Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Incidence of Sepsis
- 4.2.2 High Prevalence of Sepsis in Infants
- 4.2.3 Rise in the Number of Pipeline Products and Upsurge in Research and Development Expenditures
-
4.3 Market Restraints
- 4.3.1 Lack of Initial Diagnostic Test for identifying Sepsis Conditions and Lack of Awareness
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Class
- 5.1.1 Aminoglycosides
- 5.1.2 Cephalosporin
- 5.1.3 Glycopeptide Antibiotics
- 5.1.4 Other Drug Classes
-
5.2 By Route of Administration
- 5.2.1 Intravenous
- 5.2.2 Oral
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 F. Hoffmann-La Roche Ltd
- 6.1.2 Pfizer Inc.
- 6.1.3 GSK Plc
- 6.1.4 Viatris Inc. (Mylan Inc.)
- 6.1.5 AbbVie Inc (Allergan Pharmaceuticals Private Limited)
- 6.1.6 Asahi Kasei Corporation
- 6.1.7 RegeneRx
- 6.1.8 Inotrem SA
- 6.1.9 Endacea Inc.
- 6.1.10 Adrenomed AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Sepsis Therapeutics Industry Segmentation
As per the scope of the report, sepsis occurs when the body's response to an infection injures its own tissues and organs, potentially leading to death or significant morbidity. The sepsis therapeutics market is segmented by Drug Class (Aminoglycosides, Cephalosporin, Glycopeptide Antibiotics, and Others), Route of Administration (Intravenous and Oral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Drug Class | Aminoglycosides | |
| Cephalosporin | ||
| Glycopeptide Antibiotics | ||
| Other Drug Classes | ||
| By Route of Administration | Intravenous | |
| Oral | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Sepsis Therapeutics Market Research FAQs
What is the current Global Sepsis Therapeutics Market size?
The Global Sepsis Therapeutics Market is projected to register a CAGR of 7.60% during the forecast period (2024-2029)
Who are the key players in Global Sepsis Therapeutics Market?
Pfizer Inc., F. Hoffmann-La Roche Ltd, Viatris Inc (Mylan Inc.), GSK Plc and AbbVie Inc. (Allergan Pharmaceuticals International Limited) are the major companies operating in the Global Sepsis Therapeutics Market.
Which is the fastest growing region in Global Sepsis Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Sepsis Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Sepsis Therapeutics Market.
What years does this Global Sepsis Therapeutics Market cover?
The report covers the Global Sepsis Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Sepsis Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Veterinary Ultrasound Machines Industry Report
Statistics for the 2024 Veterinary Ultrasound Machines market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Veterinary Ultrasound Machines analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
